[
  {
    "ts": "2025-12-10T10:27:24+00:00",
    "headline": "Merck (NYSE:MRK) Could Be A Buy For Its Upcoming Dividend",
    "summary": "It looks like Merck & Co., Inc. ( NYSE:MRK ) is about to go ex-dividend in the next four days. The ex-dividend date is...",
    "url": "https://finance.yahoo.com/news/merck-nyse-mrk-could-buy-102724465.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "c9438f54-6d7a-3fef-8e57-6e1796ceef1f",
      "content": {
        "id": "c9438f54-6d7a-3fef-8e57-6e1796ceef1f",
        "contentType": "STORY",
        "title": "Merck (NYSE:MRK) Could Be A Buy For Its Upcoming Dividend",
        "description": "",
        "summary": "It looks like Merck & Co., Inc. ( NYSE:MRK ) is about to go ex-dividend in the next four days. The ex-dividend date is...",
        "pubDate": "2025-12-10T10:27:24Z",
        "displayTime": "2025-12-10T10:27:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-nyse-mrk-could-buy-102724465.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-nyse-mrk-could-buy-102724465.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T15:20:00+00:00",
    "headline": "2 Pharmaceutical Stocks to Buy at a Discount",
    "summary": "Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.",
    "url": "https://www.fool.com/investing/2025/12/10/2-pharmaceutical-stocks-to-buy-at-a-discount/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "b6bdf51d-a391-33e5-bdf1-936c0e6a305b",
      "content": {
        "id": "b6bdf51d-a391-33e5-bdf1-936c0e6a305b",
        "contentType": "STORY",
        "title": "2 Pharmaceutical Stocks to Buy at a Discount",
        "description": "",
        "summary": "Investors are currently so focused on one type of drug that even good companies are being left on the sidelines.",
        "pubDate": "2025-12-10T15:20:00Z",
        "displayTime": "2025-12-10T15:20:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/46cd4ca45406603f850c66d69dbbc6fb",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "A person kissing a piggy bank.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kYIqlUFCNxu3L_nGKO5kPA--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/46cd4ca45406603f850c66d69dbbc6fb.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hb9OHmhBzVh.uvG3PAX8oA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/46cd4ca45406603f850c66d69dbbc6fb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/12/10/2-pharmaceutical-stocks-to-buy-at-a-discount/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-pharmaceutical-stocks-buy-discount-152000549.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T16:28:41+00:00",
    "headline": "Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104",
    "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co., Inc. (NYSE:MRK) to $122 from $104 on December 5 while maintaining a Buy rating on the shares. The firm cited the inclusion of probability-adjusted revenues for Winrevair in the population investigated in […]",
    "url": "https://finance.yahoo.com/news/guggenheim-lifts-pt-merck-co-162841821.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "0bc8df6e-43c2-3f61-be2b-72a48d0816e7",
      "content": {
        "id": "0bc8df6e-43c2-3f61-be2b-72a48d0816e7",
        "contentType": "STORY",
        "title": "Guggenheim Lifts PT on Merck & Co. (MRK) to $122 From $104",
        "description": "",
        "summary": "Merck & Co., Inc. (NYSE:MRK) is one of the best pharma stocks to invest in. Guggenheim lifted the price target on Merck & Co., Inc. (NYSE:MRK) to $122 from $104 on December 5 while maintaining a Buy rating on the shares. The firm cited the inclusion of probability-adjusted revenues for Winrevair in the population investigated in […]",
        "pubDate": "2025-12-10T16:28:41Z",
        "displayTime": "2025-12-10T16:28:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Why Merck & Co (MRK) Continues to Rank Among the Most Profitable Dividend Stocks",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IzRhrl6IP..dz_8NtaA67g--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/C.KM1e7Q4T5mCkqt60S1Yg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/3c1e6d485df373db04a8fd19fdaf6c3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-lifts-pt-merck-co-162841821.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/guggenheim-lifts-pt-merck-co-162841821.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T19:13:16+00:00",
    "headline": "Immutep Limited (IMMP): Firm Reports Positive Data from Trials",
    "summary": "Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant […]",
    "url": "https://finance.yahoo.com/news/immutep-limited-immp-firm-reports-191316338.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "5b57012c-4629-3c1d-9b6b-b4923b4e4a10",
      "content": {
        "id": "5b57012c-4629-3c1d-9b6b-b4923b4e4a10",
        "contentType": "STORY",
        "title": "Immutep Limited (IMMP): Firm Reports Positive Data from Trials",
        "description": "",
        "summary": "Immutep Limited (NASDAQ:IMMP) is one of the Best Micro-Cap Stocks to Invest in According to Analysts. In mid-November, Immutep Limited (NASDAQ:IMMP) reported positive data from two clinical trials of its drug candidate eftilagimod alpha, or efti. The firm revealed that a Phase 2 study of efti in combination with radiotherapy and Merck’s Keytruda showed significant […]",
        "pubDate": "2025-12-10T19:13:16Z",
        "displayTime": "2025-12-10T19:13:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/c130a8d3ff2746185fcaa6e45e4d5380",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Immutep Limited (IMMP): Firm Reports Positive Data from Trials",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qgsRPFM3mp7.R1q5GsYC9Q--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/c130a8d3ff2746185fcaa6e45e4d5380.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/4GhQ8VLDD5ARLhwobh_q0A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/c130a8d3ff2746185fcaa6e45e4d5380.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immutep-limited-immp-firm-reports-191316338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immutep-limited-immp-firm-reports-191316338.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IMMP"
            },
            {
              "symbol": "PRRUF"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-10T19:45:00+00:00",
    "headline": "Dividend Stocks for 2026: Where to Invest as the Market Cools",
    "summary": "These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.",
    "url": "https://www.marketbeat.com/originals/dividend-stocks-for-2026-where-to-invest-as-the-market-cools/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "45f2b173-7b67-38ae-8273-1441d2855839",
      "content": {
        "id": "45f2b173-7b67-38ae-8273-1441d2855839",
        "contentType": "STORY",
        "title": "Dividend Stocks for 2026: Where to Invest as the Market Cools",
        "description": "",
        "summary": "These three dividend heavyweights offer attractive yields and upside potential heading into what could be an uncertain 2026.",
        "pubDate": "2025-12-10T19:45:00Z",
        "displayTime": "2025-12-10T19:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/8d2a6c81d66adfcdf19a5b51e8f2863c",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "A golden coin sprout emerges from rich soil beside a stacked pile of gold coins, symbolizing dividend yield and financial growth.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kK1U718Vt9auYPex8JEX_g--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/8d2a6c81d66adfcdf19a5b51e8f2863c.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.K_9xj0tXNdDLB2f9wAc8w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/8d2a6c81d66adfcdf19a5b51e8f2863c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/originals/dividend-stocks-for-2026-where-to-invest-as-the-market-cools/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dividend-stocks-2026-where-invest-194500848.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KO"
            },
            {
              "symbol": "MPLX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]